

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
10 June 2021 (10.06.2021)



(10) International Publication Number
WO 2021/113403 A1

(51) International Patent Classification:

A61K 31/337 (2006.01) A61K 31/555 (2006.01)

A61K 31/4745 (2006.01)

(21) International Application Number:

PCT/US2020/062945

(22) International Filing Date:

02 December 2020 (02.12.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/942,978 03 December 2019 (03.12.2019) US

(71) Applicant: **ONSELEX PHARMACEUTICALS, INC.**

[US/US]; 160 W. 62nd St., 7G, New York, New York 10023 (US).

(72) Inventor: **SHIN, Ernest**; Onselex Pharmaceuticals, Inc.,

160 W. 62nd St., 7G, New York, New York 10023 (US).

(74) Agent: **BORDNER, Thomas**; Prince Lobel Tye, LLP,

One International Place, Suite 3700, Boston, Massachusetts 02110 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: POLYPHOSPHAZENE DRUG CARRIERS

(57) Abstract: The present invention relates generally to hybrid polymer (e.g., polyphosphazene) based drug delivery platforms and to methods of producing, evaluating, administering, and treating subjects with the same. More particularly, the present invention provides polyphosphazene based drug delivery platforms comprising one or more polyphosphazenes with controlled molecular weights and/or polydispersities as well as selective methods for associating one or more therapeutic drug (or prodrug) substances to the polyphosphazenes.

WO 2021/113403 A1